

Supplementary material for Bjerre M, et al. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial. Scand J Clin Lab Invest 2014;74:657–64.

Supplementary Table IA. (supplementary data) Entry characteristics at study entry (1999–2000) by osteoprotegerin (OPG) quartiles.

	OPG Q1 (< 1,365 ng/L)	OPG Q2 (1,365-1,770 ng/L)	OPG Q3 (1,771-2,295 ng/L)	OPG Q4 (> 2,295 ng/L)
Male sex (%)	78	71	67	61
Age (years)	58.4	64.2	67.3	71.5
Diabetes (%)	11	13	18	19
Hypertension (%)	35	39	42	45
Previous MI (%)	70	68	68	65
Smoker/ex-smoker (%)	36/45	38/45	34/48	34/45
Statin medication (%)	50	45	40	29
Interventions:				
Clarithromycin (%)	46	52	50	50
Placebo (%)	54	48	50	50
Biomarkers:				
hsCRP (mg/L)	3.8 ($\pm$ 5.9)	5.2 ($\pm$ 7.4)	5.7 ($\pm$ 9.0)	7.4 ($\pm$ 10.6)
hscTnT (ng/L)	6.9 ($\pm$ 5.9)	9.9 ($\pm$ 21.1)	11.1 ($\pm$ 12.0)	16.9 ($\pm$ 59.0)
NT-proBNP (ng/L)	266 ($\pm$ 1037)	369 ($\pm$ 594)	498 ($\pm$ 790)	838 ($\pm$ 1535)

Percentages or mean $\pm$ SD.

High sensitive C-reactive protein (hsCRP), high-sensitivity cardiac troponin T (hscTnT), N-terminal-pro-brain natriuretic peptide (NT-proBNP).